Literature DB >> 11215366

Prospective study comparing human albumin vs. reinfusion of ultrafiltrate-ascitic fluid after total paracentesis in cirrhotic patients with tense ascites.

D Zaak1, K J Paquet, R Kuhn.   

Abstract

Although, total paracentesis associated with human albumin substitution has shown to be a rapid, effective and safe treatment of diuretic refractory ascites in advanced liver cirrhosis, it implies high costs and has a limited availability. Therefore an alternative procedure the reinfusion of concentrated ascites has gained popularity in recent years (Smart et al. 1990; Grazioto et al. 1997). It was the aim of the study to compare human albumin substitution vs. reinfusion of ascitic-ultrafiltrate after total paracentesis. 35 patients with cirrhosis and tense ascites received total paracentesis associated with either human albumin (5-8 g/l ascites) (= group A) or reinfusion of an ascitic-ultrafiltrate fluid by means of hemofiltration technique (= group B). The mean volume of ascites removed was 9.41 (2.1-20.0) in group A and 11.41 (6.5-21.0) in group B. No significant differences in serum electrolytes, liver and renal function, coagulation profiles and hormones of the renin-angiotensin-aldosterone system were observed during hospitalization. In both groups sodium excretion increased significantly. 43% of the patients in group B developed pyrexia and chill after reinfusion of the ascitic-ultrafiltrate fluid. In one patient an anaphylactic bronchospasm occurred requiring IUC-treatment. The treatment cost in case of human albumin were 326.-DM vs. 290.-DM for each patient treated with ascitic-ultrafiltrate fluid reinfusion. The probabilities of hospital readmission and survival were similar in both groups during follow-up. The results indicate that i.v. infusion of ascitic-ultrafiltrate fluid is as effective as total paracentesis and albumin infusion in case of diuretic refractory ascites. However, according to the costs of instruments and staff and due to the significant allergic reactions caused by ascitic fluid it cannot be considered as a real alternative to albumin substitution.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11215366     DOI: 10.1055/s-2001-10707

Source DB:  PubMed          Journal:  Z Gastroenterol        ISSN: 0044-2771            Impact factor:   2.000


  15 in total

Review 1.  Evidence-based clinical practice guidelines for liver cirrhosis 2015.

Authors:  Hiroshi Fukui; Hidetsugu Saito; Yoshiyuki Ueno; Hirofumi Uto; Katsutoshi Obara; Isao Sakaida; Akitaka Shibuya; Masataka Seike; Sumiko Nagoshi; Makoto Segawa; Hirohito Tsubouchi; Hisataka Moriwaki; Akinobu Kato; Etsuko Hashimoto; Kojiro Michitaka; Toshikazu Murawaki; Kentaro Sugano; Mamoru Watanabe; Tooru Shimosegawa
Journal:  J Gastroenterol       Date:  2016-05-31       Impact factor: 7.527

2.  Efficacy of tolvaptan in patients with refractory ascites in a clinical setting.

Authors:  Takamasa Ohki; Koki Sato; Tomoharu Yamada; Mari Yamagami; Daisaku Ito; Koki Kawanishi; Kentaro Kojima; Michiharu Seki; Nobuo Toda; Kazumi Tagawa
Journal:  World J Hepatol       Date:  2015-06-28

3.  Clinical usefulness of cell-free and concentrated ascites reinfusion therapy (CART) in combination with chemotherapy for malignant ascites: a post-marketing surveillance study.

Authors:  Ken Ishitani; Ayako Isoai; Tetsuya Ito; Hiroshi Sugiyama; Atsushi Arakawa; Yosuke Yamada; Hirokazu Onodera; Ryosuke Kobayashi; Naoko Torii; Noriko Soneda; Yoshihiro Matsuno; Taiju Utsugisawa; Michio Kato; Norio Hanafusa
Journal:  Int J Clin Oncol       Date:  2021-03-24       Impact factor: 3.402

4.  Use of human albumin infusion in cirrhotic patients: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Zhaohui Bai; Le Wang; Ran Wang; Meijuan Zou; Nahum Méndez-Sánchez; Fernando Gomes Romeiro; Gang Cheng; Xingshun Qi
Journal:  Hepatol Int       Date:  2022-09-01       Impact factor: 9.029

5.  Treatment for ascites in adults with decompensated liver cirrhosis: a network meta-analysis.

Authors:  Amine Benmassaoud; Suzanne C Freeman; Davide Roccarina; Maria Corina Plaz Torres; Alex J Sutton; Nicola J Cooper; Laura Iogna Prat; Maxine Cowlin; Elisabeth Jane Milne; Neil Hawkins; Brian R Davidson; Chavdar S Pavlov; Douglas Thorburn; Emmanuel Tsochatzis; Kurinchi Selvan Gurusamy
Journal:  Cochrane Database Syst Rev       Date:  2020-01-16

Review 6.  KASL clinical practice guidelines for liver cirrhosis: Ascites and related complications.

Authors: 
Journal:  Clin Mol Hepatol       Date:  2018-07-09

7.  Plasma expanders for people with cirrhosis and large ascites treated with abdominal paracentesis.

Authors:  Rosa G Simonetti; Giovanni Perricone; Dimitrinka Nikolova; Goran Bjelakovic; Christian Gluud
Journal:  Cochrane Database Syst Rev       Date:  2019-06-28

8.  Application of vacuum-assisted therapy in postoperative ascitic fluid leaks: an integral part of multimodality wound management in cirrhotic patients.

Authors:  S Peter Stawicki; Naomi S Schwarz; Sherwin P Schrag; John J Lukaszczyk; Mark E Schadt; Anthony Dippolito
Journal:  J Burns Wounds       Date:  2007-04-16

9.  Safety and efficacy of cell-free and concentrated ascites reinfusion therapy (CART) in refractory ascites: Post-marketing surveillance results.

Authors:  Norio Hanafusa; Ayako Isoai; Tomoaki Ishihara; Tetsuya Inoue; Ken Ishitani; Taiju Utsugisawa; Toshihiko Yamaka; Tetsuya Ito; Hiroshi Sugiyama; Atsushi Arakawa; Yosuke Yamada; Yasuo Itano; Hirokazu Onodera; Ryosuke Kobayashi; Naoko Torii; Toyoko Numata; Taihei Kashiwabara; Yoshihiro Matsuno; Michio Kato
Journal:  PLoS One       Date:  2017-05-16       Impact factor: 3.240

Review 10.  Evidence-based clinical practice guidelines for Liver Cirrhosis 2020.

Authors:  Hitoshi Yoshiji; Sumiko Nagoshi; Takemi Akahane; Yoshinari Asaoka; Yoshiyuki Ueno; Koji Ogawa; Takumi Kawaguchi; Masayuki Kurosaki; Isao Sakaida; Masahito Shimizu; Makiko Taniai; Shuji Terai; Hiroki Nishikawa; Yoichi Hiasa; Hisashi Hidaka; Hiroto Miwa; Kazuaki Chayama; Nobuyuki Enomoto; Tooru Shimosegawa; Tetsuo Takehara; Kazuhiko Koike
Journal:  J Gastroenterol       Date:  2021-07-07       Impact factor: 7.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.